Publications

2010-Current

  • Mitchell AA. Studies of drug-induced birth defects. In: Strom BL, Kimmel SE, Hennessy S, eds. Textbook of pharmacoepidemiology. 2nd ed (in press).
  • Yau WP, Mitchell AA, Lin KJ, Werler MM, Hernández-Díaz S. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol 2013 (in press). PMCID: PMC Journal – In Process.
  • Hernández-Díaz S, Su YC, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates among women of childbearing age. Reprod Toxicol 2013. doi: 10.1016/j.reprotox.2013.01.001 (epub ahead of print). PMCID: PMC Journal – In Process.
  • Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Safety of macrolides during pregnancy. Am J Obstet Gynecol 2013. doi: 10.1016/j.ajog.2012.12.023 (epub ahead of print). PMCID: PMC Journal – In Process.
  • Van Marter LJ, Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn. Pediatrics 2013;131:79-87. doi: 10.1542/peds.2012-0496. PMCID: PMC3529942.
  • Louik C, Chambers C, Jacobs D, Rice F, Johnson D, Mitchell AA. Influenza vaccine safety in pregnancy: can we identify exposures?. Pharmacoepidemiol Drug Saf 2013;22:33-9. doi: 10.1002/pds.3336.
  • Radin RG, Mitchell AA, Werler MM. Predictors of recall certainty of dates of analgesic medication use in pregnancy. Pharmacoepidemiol Drug Saf 2013;22:25-32. doi: 10.1002/pds.3300. PMCID: PMC3443548.
  • Kelley KE, Chaplin EL, Mitchell AA. “Phthalates”: Kelley et al. respond [letter to the editor]. Environ Health Perspect 2012;120(11):a416. doi: 10.1289/ehp.1205763R.
  • Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol 2012;22:799-806. doi: 10.1016/j.annepidem.2012.09.003. PMCID: PMC3489973.
  • Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Maternal exposure to amoxicillin and the risk of oral clefts. Epidemiology 2012;23(5):699-705. doi: 10.1097/EDE.0b013e318258cb05. PMCID: PMC Journal – In Process.
  • Margulis AV, Mitchell AA, Gilboa SM, Werler MM, Mittleman MA, Glynn RJ, Hernández-Díaz S, and the National Birth Defects Prevention Study. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207(5):405.e1-7. doi: 10.1016/j.ajog.2012.07.008. PMCID: PMC3484193.
  • Yazdy MM, Tinker SC, Mitchell AA, Demmer LA, Werler MM. Maternal tea consumption during early pregnancy and the risk of spina bifida. Birth Defects Res A Clin Mol Teratol 2012;94(10):756-61. doi: 10.1002/bdra.23025.
  • Mitchell AA. Studies of drug-induced birth defects. In: Strom BL, Kimmel SE, Hennessy S, eds. Pharmacoepidemiology. 5th ed. West Sussex, UK: Wiley-Blackwell, 2012:487-504.
  • Kelley KE, Hernández-Díaz S, Chaplin EL, Hauser R, Mitchell AA. Identification of phthalates in medications and dietary supplement formulations in the U.S. and Canada. Environ Health Perspect 2012;120(3):379-84. doi: 10.1289/ehp.1103998. PMCID: PMC3295354.
  • Collett BR, Cloonan YK, Speltz ML, Anderka M, Werler MM. Psychosocial functioning in children with and without orofacial clefts and their parents. Cleft Palate Craniofac J 2012;49(4):397-405. doi: 10.1597/10-007.
  • Mitchell AA. Fetal risk from ACE inhibitors in the first trimester–evidence is reassuring, but risks remain from the hypertension itself [editorial]. BMJ 2011;343:d6667. doi: 10.1136/bmj.d6667.
  • Yau WP, Lin KJ, Werler MM, Louik C, Mitchell AA, Hernández-Díaz S. Drug certainty-response in interview-based studies. Pharmacoepidemiol Drug Saf 2011;20:1210-6. doi: 10.1002/pds.2234. PMCID: PMC3222943.
  • Gilboa S, Broussard C, Devine O, Duwe K, Flak A, Boulet S, Moore C, Werler MM, Honein M. Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States. Am J Med Genet C Semin Med Genet 2011;157:234-46. doi: 10.1002/ajmg.c.30306.
  • Werler MM, Louik C, Mitchell AA. Case-control studies for identifying novel teratogens. Am J Med Genet C Semin Med Genet 2011;157:201-8. doi: 10.1002/ajmg.c.30307. PMCID: PMC3483035.
  • Ahrens K, Yazdy M, Mitchell AA, Werler MM. Folic acid intake and spina bifida in the era of dietary folic acid fortification. Epidemiology 2011;22(5):731-7. doi: 10.1097/EDE.0b013e3182227887.
  • Mitchell AA. Adverse drug reactions in utero: perspectives on teratogens and strategies for the future [editorial]. Clin Pharmacol Ther 2011;89:781-3. doi: 10.1038/clpt.2011.52.
  • Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S, and the National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205:51.e1-8. doi: 10.1016/j.ajog.2011.02.029. PMCID: PMC Journal – In Process.
  • Yazdy MM, Mitchell AA, Liu S, Werler MM. Maternal dietary glycaemic intake during pregnancy and the risk of birth defects. Paediatr Perinat Epidemiol 2011;25:340-6. doi:10.1111/j.1365-3016.2011.01198.x. PMCID: PMC3474333.
  • Werler MM. Birth defects. In: Buck-Louis GM, Platt RW, eds. Reproductive and perinatal epidemiology. New York: Oxford University Press, 2011:186-203.
  • Schatz M, Chambers CD, Jones KL, Louik C, Mitchell AA. The safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System. Am J Obstet Gynecol 2011;204(6 Suppl. 1):S64-8. doi: 10.1016/j.ajog.2011.01.047.
  • Dufton L, Speltz ML, Kelly JP, Leroux B, Collett BR, Werler MM. Psychosocial outcomes in children with hemifacial microsomia. J Pediatr Psychol 2011;36(7):794-805. doi: 10.1093/jpepsy/jsq112. PMCID: PMC3146752.
  • Collett BR, Speltz ML, Cloonan YK, Leroux BG, Kelly JP, Werler MM. Neurodevelopmental outcomes in children with hemifacial microsomia. Arch Pediatr Adolesc Med 2011;165(2):134-40. PMCID: PMC3142696.

2000-2010

  • Toh S, Mitchell AA, Anderka M, de Jong-van den Berg LTW, Hernández-Díaz S, and the National Birth Defects Prevention Study. Antibiotics and oral contraceptive failure: a case-crossover study. Contraception 2010;83(5):418-25. doi: 10.1016/j.contraception.2010.08.020.
  • Hernandez RK, Mitchell AA, Werler MM. Decongestant use during pregnancy and its association with preterm delivery. Birth Defects Res A Clin Mol Teratol 2010;88:715-21.
  • Louik C, Schatz M, Hernández-Díaz S, Werler MM, Mitchell AA. Asthma in pregnancy and its pharmacologic treatment. Ann Allergy Asthma Immunol 2010;105:110-7. PMCID: PMC2953247.
  • Mitchell AA. Proton-pump inhibitors and birth defects–some reassurance, but more needed [editorial]. N Engl J Med 2010;363(22):2161-3.
  • Louik C, Gardiner P, Kelley K, Mitchell AA. Use of herbal treatments in pregnancy. Am J Obstet Gynecol 2010;202(5):439.e1-10. PMCID: PMC2867842.
  • Burris HH, Mitchell AA, Werler MM. Periconceptional multivitamin use and its association with infant birth weight disparities. Ann Epidemiol 2010;20:233-40. doi: 10.1016/j.annepidem.2009.12.003.
  • Werler MM. Hypothesis: could Epstein-Barr virus play a role in the development of gastroschisis? Birth Defects Res A Clin Mol Teratol 2010;88(2):71-5. doi: 10.1002/bdra.20640.
  • Yazdy MM, Liu S, Mitchell AA, Werler MM. Maternal dietary glycemic intake and the risk of neural tube defects. Am J Epidemiol 2010;171(4):407-14. doi: 10.1093/aje/kwp395. PMCID: PMC2842193.
  • Hobbs CA, Shaw GM, Werler MM, Mosley B. Folate status and birth defect risk: epidemiological perspective. In: Bailey LB, ed. Folate in health and disease. 2nd ed. Boca Raton, FL: CRC Press, 2009:133-54.
  • Toh S, Mitchell AA, Louik C, Werler MM Chambers CD, Hernández-Díaz S. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009;29(6):555-60. doi: 10.1097/JCP.0b013e3181bf344c. PMCID: PMC3206605.
  • Cloonan YK, Kifle Y, Davis S, Speltz ML, Werler MM, Starr JR. Sleep outcomes in children with hemifacial microsomia and controls: a follow-up study. Pediatrics 2009;124(2):e313-21. doi: 10.1542/peds.2008-3488. PMCID: PMC2739665.
  • Li L, Werler MM. Fruit and vegetable intake and risk of upper respiratory tract infection in pregnant women. Public Health Nutr 2009;13(2):276-82. doi: 10.1017/S1368980009990590. PMCID: PMC2808435.
  • Werler MM, Starr JR, Cloonan YK, Speltz ML. Hemifacial microsomia: from gestation to childhood. J Craniofac Surg 2009;20(Suppl. 1):664-9. PMCID: PMC2791372.
  • Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernández-Díaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry 2009;166:320-8. doi: 10.1176/appi.ajp.2008.08060817. PMCID: PMC2735348.
  • Mitchell AA. Prescription medication sharing [letter to the editor]. Am J Public Health 2008;98(11):1926-7. doi: 10.2105/AJPH.2008.144261.
  • Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA, and the National Birth Defects Prevention Study. Maternal exposure to statins and risk for birth defects: a case-series approach [research letter]. Am J Med Genet A 2008;146A(20):2701-5. doi: 10.1002/ajmg.a.32493.
  • Nelson JW, Werler MM. Socioeconomic status as a modifier of the relationship between antibiotic use during pregnancy and birthweight. Birth 2008;35(3):196-203. doi: 10.1111/j.1523-536X.2008.00240.x.
  • Toh S, Mitchell AA, Werler MM, Hernández-Díaz S. Toh et al. respond to “Compromise or compromising?” [commentary]. Am J Epidemiol 2008;167(6):644-5. doi: 10.1093/aje/kwm369.
  • Toh S, Mitchell AA, Werler MM, Hernández-Díaz S. Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol 2008;167(6):633-40. doi: 10.1093/aje/kwm367.
  • Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007;120(2);272-82.
  • Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83.
  • Leeder JS, Mitchell AA. Application of pharmacogenomic strategies to the study of drug-induced birth defects. Clin Pharmacol Ther 2007;81(4):595-9.
  • Werler MM. Maternal smoking and undescended testes: reaching a tipping point [commentary]. Epidemiology 2007;18:197-8.
  • Badovinac RL, Werler MM, Williams PL, Kelsey KT, Hayes C. Folic acid-containing supplement consumption during pregnancy and risk for oral clefts: a meta-analysis. Birth Defects Res A Clin Mol Teratol 2007;79:8-15.
  • Hernández-Díaz S, Schisterman EF, Hernán MA. Hernández-Díaz et al. respond to “The perils of birth weight” [commentary]. Am J Epidemiol 2006;164:1124-5.
  • Hernández-Díaz S, Schisterman EF, Hernán MA. The birth weight “paradox” uncovered? Am J Epidemiol 2006;164:1115-20.
  • Meijer WM, Werler MM, Louik C, Hernández-Díaz S, de Jong-van den Berg LTW, Mitchell AA. Can folic acid protect against congenital heart defects in Down syndrome? Birth Defects Res A Clin Mol Teratol 2006;76(10):714-7.
  • Werler MM. Teratogen update: pseudoephedrine. Birth Defects Res A Clin Mol Teratol 2006;76(6):445-52.
  • Louik C, Hernández-Díaz S, Werler MM, Mitchell AA. Nausea and vomiting in pregnancy: maternal characteristics and risk factors. Paediatr Perinat Epidemiol 2006;20:270-8.
  • Chambers CD, Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354(6):579-87.
  • Mitchell AA. Prone to sleep, prone to pyloric stenosis? [commentary]. Epidemiology 2006;17:136-7.
  • Werler MM, Mitchell AA, Hernández-Díaz S, Honein MA, and the National Birth Defects Prevention Study. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 2005;193:771-7.
  • Hernández-Díaz S, Wu XF, Hayes C, Werler MW, Ashok TDS, Badovinac R, Kelsey KT, Mitchell AA. Methylenetetrahydrofolate reductase polymorphisms and the risk of gestational hypertension. Epidemiology 2005;16(5):628-34.
  • Mitchell AA. Studies of drug-induced birth defects. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. New York: Wiley, 2005:501-15.
  • Louik C, Mitchell AA. Post-marketing surveillance using pharmacy-based cohorts: results of a pilot study. Pharmacoepidemiol Drug Saf 2005;14:289-95.
  • de Jong-van den Berg LTW, Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Trends and predictors of folic acid awareness and periconceptional use in pregnant women. Am J Obstet Gynecol 2005;192:121-8.
  • Werler MM, Sheehan JE, Mitchell AA. Gulf war veterans and hemifacial microsomia. Birth Defects Res A Clin Mol Teratol 2005;73:50-2.
  • Chan KA, Hernández-Díaz S. Pharmacoepidemiology and rheumatic disorders. Rheum Dis Clin North Am 2004;30(4):835-50.
  • Meyer K, Williams P, Hernández-Díaz S, Cnattingius S. Smoking and the risk of oral clefts: exploring the impact of study designs. Epidemiology 2004;15(6):671-8.
  • Werler MM, Sheehan JE, Hayes C, Padwa BL, Mitchell AA, Mulliken JB. Demographic and reproductive factors associated with hemifacial microsomia. Cleft Palate Craniofac J 2004;41:494-500.
  • Werler MM, Sheehan JE, Hayes C, Mitchell AA, Mulliken JB. Vasoactive exposures, vascular events, and hemifacial microsomia. Birth Defects Res A Clin Mol Teratol 2004;70(6):389-95.
  • Mitchell AA. Systematic identification of drugs that cause birth defects–a new opportunity [editorial]. N Engl J Med 2003;349:2556-9.
  • Hernández-Díaz S, de Abajo FJ. Psychomotor development in children and antenatal psychotropic and anti-epileptic drugs [commentary]. Eur J Epidemiol 2003;18(8):743-4.
  • Hernández-Díaz S, Hernán MA, Meyer K, Werler MM, Mitchell AA. Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol 2003;158:385-91.
  • Meyer KA, Werler MM, Hayes C, Mitchell AA. Low maternal alcohol consumption during pregnancy and oral clefts in offspring: the Slone Birth Defects Study. Birth Defects Res A Clin Mol Teratol 2003;67:509-14.
  • Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology 2003;14:349-54.
  • Louik C, Mitchell AA. Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis [letter to the editor]. Obstet Gynecol 2003;101(4):816.
  • Waller DK, Tita ATN, Werler MM, Mitchell AA. Association between pre-pregnancy maternal body mass index and the risk of having an infant with a congenital diaphragmatic hernia. Birth Defects Res A Clin Mol Teratol 2003;67:73-6.
  • Werler MM, Louik C, Mitchell AA. Epidemiologic analysis of maternal factors and amniotic band defects. Birth Defects Res A Clin Mol Teratol 2003;67:68-72.
  • Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. Am J Epidemiol 2002;156:806-12.
  • Werler MM. Exposure assessment in studies of oral clefts. In: Wyszynski DF, ed. Cleft lip and palate: from origin to treatment. New York: Oxford University Press, 2002:108-16.
  • Hernández-Díaz S. Iatrogenic legacy from diethylstilbestrol exposure [commentary]. Lancet 2002;359:1081-2.
  • Mitchell AA. Infertility treatment–more risks and challenges [editorial]. N Engl J Med 2002;346:769-70.
  • Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in relation to pyloric stenosis. Am J Obstet Gynecol 2002;186:288-90.
  • Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002;155:26-31.
  • Hernán MA, Hernández-Díaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 2002;155:176-84.
  • Werler MM. Additional insights into the etiology of cardiac anomalies [editorial]. Epidemiology 2001;12:482-4.
  • Kaufman DW, Rosenberg L, Mitchell AA. Signal generation and clarification: use of case-control data. Pharmacoepidemiol Drug Saf 2001;10:197-203.
  • Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961-8.
  • Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14.
  • Mitchell AA. Special considerations in studies of drug-induced birth defects. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. Chichester, UK: John Wiley and Sons, 2000:749-63.
  • Louik C, Frumkin H, Ellenbecker MJ, Goldman RH, Werler MM, Mitchell AA. Use of a job-exposure matrix to assess occupational exposures in relation to birth defects. J Occup Environ Med 2000;42:693-703.
  • Werler MM, Mitchell AA. Folic acid and neural tube defect risk [letter to the editor]. N Engl J Med 2000;342:1135-6.

1990-2000

  • Werler MM, Louik C, Mitchell AA. Achieving a public health recommendation for preventing neural tube defects with folic acid. Am J Public Health 1999;89:1637-40.
  • Lieff S, Olshan AF, Werler M, Strauss RP, Smith J, Mitchell A. Maternal cigarette smoking during pregnancy and risk of oral clefts in newborns. Am J Epidemiol 1999;150:683-94.
  • Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. Am J Epidemiol 1999;150:675-82.
  • Lieff S, Olshan AF, Werler M, Savitz DA, Mitchell AA. Selection bias and the use of controls with malformations in case-control studies of birth defects. Epidemiology 1999;10:238-41.
  • Mitchell AA. Intracytoplasmic sperm injection: offering hope for a term pregnancy and a healthy child? [editorial]. BMJ 1997;315:1245-6.
  • Werler MM. Teratogen update: smoking and reproductive outcomes. Teratology 1997;55:382-8.
  • Werler MM, Cragan JD, Wasserman CR, Shaw GM, Erickson JD, Mitchell AA. Multivitamin supplementation and multiple births. Am J Med Genet 1997;71:93-6.
  • Hayes C, Werler MM, Willett WC, Mitchell AA. Case-control study of periconceptional folic acid supplementation and oral clefts. Am J Epidemiol 1996;143:1229-34.
  • Werler MM, Louik C, Shapiro SS, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. J Am Med Assoc 1996;275:1089-92.
  • Werler MM, Mitchell AA. More on folic acid and neural tube defects [letter to the editor]. Am J Public Health 1995;85:269.
  • Mitchell AA, Werler MM, Shapiro S. Response to the commentary “Should we consider a subject’s knowledge of the etiologic hypothesis in the analysis of case-control studies?” [commentary]. Am J Epidemiol 1995;141:297-8.
  • Mitchell AA. Special considerations in studies of drug-induced birth defects. In: Strom BL, ed. Pharmacoepidemiology. 2nd ed. Chichester, UK: John Wiley and Sons, 1994:595-608.
  • Werler MM, Louik C, Shapiro S, Mitchell AA. Ovulation induction and risk of neural tube defects. Lancet 1994;344:445-6.
  • Werler MM, Mitchell AA. Case-control study of vitamin supplementation and neural tube defects: consideration of potential confounding by lifestyle factors. Ann N Y Acad Sci 1993;678:276-83.
  • Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. J Am Med Assoc 1993;269:1257-61.
  • Mitchell AA, Werler MM, Shapiro S. Analyses and reanalyses of epidemiologic data: learning lessons and maintaining perspective [commentary]. Teratology 1992;46:209-11.
  • Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992;45:361-7.
  • Werler MM, Mitchell AA, Shapiro S. Demographic, reproductive, medical, and environmental factors in relation to gastroschisis. Teratology 1992;45:353-60.
  • Mitchell AA. Oral retinoids: what should the prescriber know about their teratogenic hazards among women of child-bearing potential? Drug Saf 1992;7:79-85.
  • Werler MM, Lammer EJ, Rosenberg L, Mitchell AA. Maternal alcohol use in relation to selected birth defects. Am J Epidemiol 1991;134:691-8.
  • Mitchell AA. Teratogens and the dermatologist: new knowledge, responsibilities, and opportunities [editorial]. Arch Dermatol 1991;127:399-401.

1980-1990

  • Werler MM, Lammer EJ, Rosenberg L, Mitchell AA. Maternal vitamin A supplementation in relation to selected birth defects. Teratology 1990;42:497-503.
  • Werler MM, Lammer EJ, Rosenberg L, Mitchell AA. Maternal cigarette smoking during pregnancy in relation to oral clefts. Am J Epidemiol 1990;132:926-32.
  • Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989;321:1639-42.
  • Mitchell AA. Slone Epidemiology Unit Birth Defects Study. Genetic Resour 1988;4:31-2.
  • Louik C, Mitchell A, Werler M, Hanson J, Shapiro S. Maternal exposure to spermicides in relation to certain birth defects. N Engl J Med 1987;317:474-8.
  • Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670-6.
  • Mitchell AA, Schwingl PJ, Rosenberg L, Louik C, Shapiro S. Birth defects in relation to Bendectin use in pregnancy: pyloric stenosis. Am J Obstet Gynecol 1983;147:737-42.
  • Rosenberg L, Mitchell AA, Parsells J, Pashayan H, Louik C, Shapiro S. Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 1983;309:1282-5.
  • Shapiro S, Slone D, Heinonen OP, Kaufman DW, Rosenberg L, Mitchell AA, Helmrich SP. Birth defects and vaginal spermicides. J Am Med Assoc 1982;247:2381-4.
  • Rosenberg L, Mitchell AA, Shapiro S, Slone D. Selected birth defects in relation to caffeine-containing beverages. J Am Med Assoc 1982;247:1429-32.
  • Mitchell AA, Rosenberg L, Shapiro S, Slone D. Birth defects related to Bendectin use in pregnancy: oral clefts and cardiac defects. J Am Med Assoc 1981;245:2311-4.
  • Slone D, Shapiro S, Mitchell AA. Strategies for studying the effects of the antenatal chemical environment on the fetus. In: Schwarz RH, Yaffe SJ, eds. Drug and chemical risks to the fetus and newborn. New York: Alan R. Liss, Inc., 1980.